| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Simon Barry J. | Director | C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO | /s/ Philip LoScalzo, as Attorney-in-Fact | 21 Jan 2026 | 0001647994 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IBRX | Common Stock | Sale | $503,364 | -76,967 | -2.4% | $6.54* | 3,166,604 | 20 Jan 2026 | Direct | F1 |
| transaction | IBRX | Common Stock | Sale | $590,932 | -75,000 | -2.4% | $7.88* | 3,091,604 | 20 Jan 2026 | Direct | F1, F2 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. |
| F2 | Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $7.87 to $7.8950 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Exhibit 24 - Power of Attorney